Apontis Pharma AG Asset Resilience Ratio
Apontis Pharma AG asset resilience ratio. Apontis Pharma AG (APPH) has an Asset Resilience Ratio of -1.20% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Apontis Pharma AG (APPH) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Apontis Pharma AG (2019–2023)
Asset resilience ratio of Apontis Pharma AG from 2019 to 2023. This chart shows how Apontis Pharma AG's Asset Resilience Ratio has changed over time. Read Apontis Pharma AG total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Apontis Pharma AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Apontis Pharma AG's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €-643.20K | -1.2% |
| Total Liquid Assets | €-643.20K | -1.20% |
Asset Resilience Insights
- Limited Liquidity: Apontis Pharma AG maintains only -1.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Apontis Pharma AG Industry Peers by Asset Resilience Ratio
Compare Apontis Pharma AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Apontis Pharma AG Asset Resilience Ratio by Year (2019–2023)
Apontis Pharma AG asset resilience ratio by year from 2019 to 2023. The table below shows the annual Asset Resilience Ratio data for Apontis Pharma AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.52% | €-301.15K ≈ $-352.08K |
€57.46 Million ≈ $67.18 Million |
+0.30pp |
| 2022-12-31 | -0.82% | €-490.42K ≈ $-573.36K |
€59.85 Million ≈ $69.97 Million |
+0.17pp |
| 2021-12-31 | -0.99% | €-536.59K ≈ $-627.33K |
€54.13 Million ≈ $63.29 Million |
-3.14pp |
| 2020-12-31 | 2.15% | €638.66K ≈ $746.66K |
€29.69 Million ≈ $34.71 Million |
+0.22pp |
| 2019-12-31 | 1.93% | €590.66K ≈ $690.54K |
€30.59 Million ≈ $35.76 Million |
-- |
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more